诺华-肿瘤学会 ASCO2021.pdfVIP

Novartis Investor Relations Novartis Oncology Update Post-ASCO investor presentation June 8, 2021 Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar terms, or by express or implied discussions regarding the potential future success of our Oncology business unit, potential marketing approvals, new indications or labeling for the investigational and approved products described in this presentation, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that our Oncology business unit will succeed or achieve any or all of its goals in the future, or at any particular time, or that the investigational or approved products described in this presentation will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarant ee that our Oncology business unit or such products will be commercially successful in the future. In particular, our expectations regarding our Oncology business unit and such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions o